Natixis Advisors LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Natixis Advisors LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,002 shares of the biopharmaceutical company’s stock, valued at approximately $2,751,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Plato Investment Management Ltd increased its stake in shares of Alnylam Pharmaceuticals by 2,666.3% in the 1st quarter. Plato Investment Management Ltd now owns 4,509 shares of the biopharmaceutical company’s stock worth $674,000 after acquiring an additional 4,346 shares during the last quarter. Diversified Trust Co purchased a new position in Alnylam Pharmaceuticals during the second quarter worth about $1,210,000. Los Angeles Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock valued at $37,684,000 after purchasing an additional 135,829 shares during the last quarter. Breakwater Capital Group purchased a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at approximately $249,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth approximately $578,000. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Wolfe Research downgraded Alnylam Pharmaceuticals from a “peer perform” rating to an “underperform” rating in a research report on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. The Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their price target for the company from $198.00 to $370.00 in a research report on Friday, August 16th. Finally, Barclays upped their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $298.09.

Alnylam Pharmaceuticals Stock Down 0.8 %

Shares of ALNY stock opened at $244.89 on Monday. The company has a market capitalization of $31.59 billion, a price-to-earnings ratio of -93.47 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39. The firm has a fifty day moving average of $273.13 and a 200-day moving average of $238.67. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The firm’s quarterly revenue was down 33.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.15 earnings per share. As a group, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.